Novartis Zortress medication wins FDA nod to prevent liver transplantation ... Pharmaceutical Business Review Zortress, which is cleared for use in adults subsequent to liver transplantation, binds to mammalian target of rapamycin (mTOR) and acts with calcineurin inhibitors (CNIs) thereby, lessening the probability of CNI exposure. Novartis division head David ... FDA grants fresh approval for Novartis' Zortress Novartis' Zortress cleared by FDA for liver transplants |
